Serotonin-1A receptors in the dorsal periaqueductal gray matter mediate the panicolytic-like effect of pindolol and paroxetine combination in the elevated T-maze  by Sela, Vânia Ramos et al.
S
p
e
V
F
a
b
c
a
A
R
R
A
K

5
D
A
P
S
s
i
[
s
r
b
e
p
t
a
a
i
p
o
s
v
a
0
dNeuroscience Letters 495 (2011) 63–66
Contents lists available at ScienceDirect
Neuroscience Letters
journa l homepage: www.e lsev ier .com/ locate /neule t
erotonin-1A receptors in the dorsal periaqueductal gray matter mediate the
anicolytic-like effect of pindolol and paroxetine combination in the
levated T-maze
ânia Ramos Selaa, Carla Biesdorfa, Diego Henrique Ramosa, Hélio Zangrossi Jr. b,
rederico Guilherme Graeff c, Elisabeth Aparecida Audia,∗
Department of Pharmacology and Therapeutic, State University of Maringá, Av. Colombo, 5790 – Jardim Universitário, CEP: 87020900 Maringá, PR, Brazil
Department of Pharmacology, School of Medicine of Ribeirão Preto, University of São Paulo, Ribeirão Preto, SP, Brazil
Department of Neurosciences and Behavioral Sciences, School of Medicine of Ribeirão Preto, University of São Paulo, Ribeirão Preto, SP, Brazil
r t i c l e i n f o
rticle history:
eceived 22 December 2010
eceived in revised form 9 March 2011
ccepted 13 March 2011
eywords:
a b s t r a c t
The -adrenergic blocker and 5-HT1A receptor antagonist pindolol has been combined with selective
serotonin reuptake inhibitors (SSRIs) in patients with depressive and anxiety disorders to shorten the
onset of the clinical action and/or increase the proportion of responders. The results of a previous study
have shown that pindolol potentiates the panicolytic effect of paroxetine in rats submitted to the elevated
T-maze (ETM). Since reported evidence has implicated the 5-HT1A receptors of the dorsal periaqueductal-Adrenergic antagonist
-HT1A receptor
orsal periaqueductal gray
ntidepressant
anic disorder
graymatter (DPAG) in the panicolytic effect of antidepressants, rats treatedwith pindolol (5.0mg/kg, i.p.)
and paroxetine (1.5mg/kg, i.p.) received a previous intra-DPAG injection of the selective 5-HT1A antago-
nist,WAY-100635 (0.4g) andwere submitted to the ETM. PretreatmentwithWAY-100635 reversed the
increase inescape latency, apanicolytic effect, determinedby thepindolol-paroxetinecombination. These
results implicate the 5-HT1A receptors of the DPAG in the panicolytic effect of the pindolol-paroxetine
combination administered systemically. They also give further preclinical support for the use of this drug
entcombination in the treatm
elective serotonin (5-HT) reuptake inhibitors (SSRIs) have been
uccessfully used for the treatment of several anxiety disorders,
ncluding generalized anxiety (GAD) [13,20], panic disorder (PD)
25], in addition to depressive disorders [29]. Although antidepres-
ant treatments are effective, they have a slow onset of action,
esulting in a delay of several weeks before clinical improvement
ecomes signiﬁcant [26]. They may also produce an initial exac-
rbation of anxiety symptoms, especially in PD [5]. An additional
roblem is the resistance of nearly 30% of treated patients to this
herapeutic approach [28].
Clinical studies have shown that the association of a -
drenergic blocker such as pindolol,which is also a 5-HT1A receptor
ntagonist, generally hastens the antidepressant effect [1,18],
ntensiﬁes the panicolytic effect of SSRIs in treatment-resistant
anic patients [11,38] and further reduces panic symptomatol-
gy [36,37]. These effects have been attributed to the blockade of
omatodendritic 5-HT1A receptors [10,21], but criticisms on this
iew have been raised [3,24]. In addition, negative results have
lso been reported [4,30] which have been interpreted on the basis
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of methodological differences among studies, such as the use of
suboptimal doses of pindolol (for further details see [24]).
A recent study performed in this laboratory has shown that
the combination of ineffective doses of pindolol and of the SSRI
paroxetine signiﬁcantly increase escape latency in rats submitted
to elevated T-maze (ETM), indicating a selective panicolytic effect
[23]. The ETM is an animal model that measures both inhibitory
avoidance and one-way escape in the same rat, tasks which have
been related to the GAD and PD, respectively [9].
On the basis of preclinical [35] and clinical [8] results, seroton-
ergic mechanisms that control defensive behavior in the dorsal
periaqueductal gray matter (DPAG) have been implicated in the
pathophysiology of PD and in the therapeutic action of antidepres-
sant drugs. Particularly, 5-HT1A and 5-HT2A receptors localized in
this brain structure have been shown to mediate panicolytic drug
effects in two animal models of panic, namely the ETM and the
electrical stimulation of the DPAG [16,22,35].
To evaluate the participation of the 5-HT1A receptors of the
Open access under the Elsevier OA license.DPAG in the panicolytic effect of the combination of pindolol and
paroxetine, we have presently veriﬁed whether a previous injec-
tion of the 5-HT1A antagonist WAY-100635 into the DPAG would
reduce the panicolytic effect of the systemic administration of the
pindolol-paroxetine combination measured in the ETM.
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Male Wistar rats (n=44) weighing 230–250g were housed in
roups of four or ﬁve and given free access to food and water. Tem-
eraturewas kept at 22±1 ◦C, and a 12-h light-dark cycle (lights on
t 07:00) was maintained throughout the experiments. The exper-
mental procedures adopted had been approved by the UEM Ethics
ommittee (062/2007-CEEA), and follow the Biomedical Research
nvolving Animals (CIMS) recommendations (Geneva, 1985).
The ETM was made of wood and had three arms of equal dimen-
ions (50 cm×12 cm). One arm, enclosed by 40 cm high walls, was
erpendicular to two opposed open arms. To avoid falls, the open
rms were surrounded by a 1-cm high Plexiglas rim. The whole
pparatus was elevated 50 cm above the ﬂoor. The open-ﬁeld test
as performed in awooden round box (70 cmdiameter)withwalls
0 cm high. Luminosity on the maze arms or on the circular arena
enter was 60 lux.
The following drugs were used: 1[1H-indol-4-yloxy]-3-
isopropylamino]-2-propanolol (D, L pindolol; Sigma, USA),
aroxetine (IPCA Laborat, India) and N-[2-[4-(2-methoxyphenyl)-
-piperazinyl]ethyl]-N-2-pyridinyl-cyclohexanecarboxamide
aleate (WAY-100635; Sigma, USA). Drugs were dissolved in a
olution containing sterile saline with 2% Tween 80, except for
AY-100635, which was dissolved in sterile saline. All drugs were
reshly prepared, 30min before injections.
Rats anesthetized with ketamine (70mg/kg, Virbac, Brazil)
nd xylazine (12mg/kg, Vetbrands, Brazil) by the intramuscu-
ar route, associated with local anesthesia (2% xylocaine with
drenaline, Bravet laboratory, Brazil), were positioned in a stereo-
axic frame (David-Kopf). A stainless-steel guide cannula (12mm
ong; outer and inner diameter 0.6mm and 0.4mm, respectively)
as implanted 1.4mm above the DPAG for microinjection. The
tereotaxic coordinates from the Paxinos and Watson [17] with
eference to bregma were: posterior −6.6mm, lateral 2.0mm,
nd deep 3.6mm, at an angle of 22◦. The stainless-steel guide
annula was ﬁxed to the skull with stainless-steel screws and self-
olymerizing acrylate resin, and closed with a stainless-steel wire
o prevent obstruction. Following this procedure, the animals were
reated with an antibiotic preparation by the intramuscular route
benzylpenicilin and streptomycin, Fort Dodge, Brazil) to prevent
nfection.
On theﬁfth and sixthdays after the surgery, animalswere gently
andled for 5min and, on the sixth day, were exposed to one of the
pen arms of the ETM for 30min. Awooden barriermounted on the
order of the maze central area and the open arm’s proximal end
solated this arm from the rest of the maze. It has been shown that
rior exposure to one of the open arms of the maze decreases the
atencies to leave this arm on a later trial and renders the escape
ask sensitive to chronic antidepressant treatment, probably due to
abituation to theopenarm,eliminating the inhibitory interference
f novelty on escape performance [27,32].
On the seventhday, animalswere tested in both the ETMand the
pen-ﬁeld. After randomization, rats were administered intraperi-
ig. 1. Diagrammatic representation of coronal sections through the rat brain showing th
ewer than the total number of rats used because of several overlaps.etters 495 (2011) 63–66
toneally (i.p.) with pindolol (5.0mg/kg, Pin) or vehicle solution
(Veh), 20min before paroxetine (1.5mg/kg, Par) or Veh, and 50min
laterwere injected into theDPAGwith eitherWAY-100635 (0.4g)
or saline. Thus, the followinggroupswere formed:Veh+Veh i.p./Sal
DPAG (control; n=12), Veh+Veh i.p./WAY DPAG (n=11), Pin +Par
i.p./Sal DPAG (n=10), Pin +Par i.p./WAYDPAG (n=11). After 40min
from the intra-DPAG injection, animals were submitted to the
behavioral tests. The behaviors were scored by an experimenter
blind to the treatments.
For intra-DPAG injections (WAY-100635 or saline), a needle
(0.3mm outer diameter) was introduced through the guide can-
nula until its tip was 1.4mm below the cannula end. A volume of
0.2l was injected over a period of 2min (0.1l/min) using a 10l
microsyringe (Hamilton 701-RN, USA) attached to a microinfusion
pump (KD Scientiﬁc, USA). The intra-cerebral needle was removed
1min after the injection was ﬁnished.
The test in the ETM was initiated by the inhibitory avoidance
task. To this end, each animal was placed at the distal end of the
enclosed arm of the ETM facing the intersection of the arms. The
time taken by the rat to leave this arm with the four paws was
recorded (baseline latency). The same measurement was repeated
in two subsequent trials (avoidance 1 and 2) at 30-s intervals. Fol-
lowing avoidance training (30 s), rats were placed at the end of the
same, previously experienced open arm, and the latency to leave
this arm with the four paws was recorded for three consecutive
times (escape1, 2 and3) at 30 s inter-trial intervals. A cut-off timeof
300 swas established for the avoidance and escape latencies. Thirty
seconds after being tested in the ETM, each animal was placed for
5min in the open-ﬁeld for the evaluation of locomotion. The total
distance traveled was recorded by a video tracking system (Ethovi-
sion; Noldus, Holland). The behavioral tests have been conducted
from 08:00 to 13:00h.
After the experiments, animals were anesthetized with sodium
pentobarbital (Cristália, Brazil) by the i.p. route, and their brains
were perfused intracardially with saline solution (0.9% NaCl) fol-
lowed by 10% formalin solution before being removed and ﬁxed
in 10% formalin. Brain slices of 50m were sectioned by means
of a microtome in order to localize the site of the drug injection,
according to the Paxinos and Watson’s atlas [17]. Only animals
with injection sites located inside the DPAG were included in the
statistical analysis (see Fig. 1).
Repeated-measures analysis of variance (RM-ANOVA) was used
to analyze both avoidance and escape data, with drug treatment
as the independent factor and trial as the repeated measure. When
appropriate, one-way ANOVA followed by the post hoc Duncan’s
multiple comparison tests was used. Locomotor activity data were
analyzed by one-way ANOVA followed by the same Duncan’s
test. Differences between groups were considered signiﬁcant if
p≤0.05.
Fig. 1 depicts the sites of drug injections of animals tested in the
current study.
e location of injection sites inside (squares) DPAG. The number of points shown is
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Table 1
Effect (mean± SEM) of intra-DPAG injection of WAY-100635 on inhibitory avoidance latencies on ETM and distance traveled in the open ﬁeld of rats treated with pindolol
and paroxeline combination.
Treatment Baseline (s) Avoidance 1 (s) Avoidance 2 (s) Distance traveled (m)
± 13.
± 14.
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oVeh+Veh i.p/Sal DPAG 23.0 ± 4.3 17.2
Veh+Veh i.p./WAY DPAG 15.2 ± 4.5 15.0
Pin +Par i.p/Sal DPAG 12.1 ± 4.7 54.8
Pin +Par i.p./WAY DPAG 18.3 ± 4.5 41.2
Theeffect of drug treatmentsonescapeperformance canbe seen
n Fig. 2. The RM-ANOVA revealed a signiﬁcant effect of treatment
F(3,40) =6.40; p<0.01] and of trial [F(2,80) =5.38; p<0.01], but no
igniﬁcant trial by treatment interaction [F(6,80) =1.74; p=0.12].
hepost hoc test revealed that thepindolol-paroxetinecombination
igniﬁcantly increased escape 1 latency, and that the intra-DPAG
njection of WAY-100635 abolished this effect (p<0.01).
The drug treatments employed did not interfere with either
nhibitory avoidance acquisition or locomotion in the open-ﬁeld
see Table 1).
The ﬁndings conﬁrm previously reported results [23] show-
ng that the acute administration of the -adrenergic and 5-HT1A
eceptor antagonist pindolol combined with the SSRI paroxetine
as a panicolytic effect, indicated by the signiﬁcant increase of
scape latency in the ETM. More importantly, they additionally
how that previous intra-DPAGmicroinjection of the 5-HT1A recep-
or antagonist WAY-100635 counteracts the panicolytic effect of
his drug combination.
Since the different treatments presently used did not signif-
cantly modify the total distance traveled by the animals in the
pen-ﬁeld the observed effects in the ETM are unlikely to be due to
on-speciﬁc alterations in motor function.
Several reported results have shown that pindolol blocks5-HT1A
utoreceptors of the raphe nuclei more effectively than 5-HT1A
ostsynaptic receptors located in limbic areas [14,21]. This prop-
rty may be responsible for the blockade of the SSRI-induced
nhibition of 5-HT cell ﬁring and potentiation the SSRIs therapeutic
ffect [2]. Yet, autoradiographic and positron emission tomography
PET) studies have questioned this view, since their results have
hown that at clinically-used doses pindolol (7.5mg/day) occupies
nly a moderate number of 5-HT1A receptors in the human brain
3,24].Although the mechanism of the clinical action of the pindolol-
SRI combination is a matter of debate, preclinical evidence has
learly shown that pindolol potentiates the increase of extracellu-
ar levels of 5-HT determined by SSRIs in different brain regions
ig. 2. Effect (mean± SEM) of intra-DPAG injection of WAY-100635 (0.4g) or
aline on one-way escape latency of rats treated with pindolol (5.0mg/kg, i.p.) and
aroxetine (1.5mg/kg, i.p.) combination (n=10–12). *p<0.05, compared with all
ther groups in the same trial.
[5 50.2 ± 32.8 17.9 ± 1.3
1 78.4 ± 34.2 21.3 ± 1.4
8 160.4 ± 35.9 18.7 ± 1.4
1 100.3 ± 34.2 16.3 ± 1.4
[6,12,15,21], although there is one study that found no such effect
of selective 1 or 2-adrenergic antagonists in the frontal cortex
[12].
The ﬁnding that blockade of 5-HT1A receptors in the DPAG
prevent the panicolytic effect of the combined administration of
pindolol andparoxetine is consonantwith reportedevidence show-
ing that chemical stimulation of the dorsal raphe nucleus enhances
5-HT extracellular levels in the DPAG, measured by in vivo micro-
dialysis [31], and that pretreatmentwith an intra-DPAG injection of
WAY-100635 antagonizes the anti-escape effect of this raphe stim-
ulation in the ETM [19]. In addition, previously reported results
have shown that 5-HT1A (and 5-HT2A) receptor agonists injected
into the DPAG inhibit the escape response generated by electrical
stimulation of the same brain area [7,16,22] as well as intermedi-
ate the panicolytic effect of chronic treatmentwith SSRIs, including
imipramine, ﬂuoxetine, sertraline, measured in the ETM [33–35].
In summary, the results show that the intra-DPAG injection of
the selective 5-HT1A receptor antagonist WAY-100635 counteracts
the anti-escape effect of the systemic administration of a pindolol-
paroxetine combination in the ETM. Therefore 5-HT1A receptors
located in the DPAG are likely to mediate the panicolytic-effect of
this drug combination. These results also give further preclinical
support for the use of this drug combination in the treatment of
PD.
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